Slingshot members are tracking this event:
Ionis Pharma (IONS) to finish Phase 2 study of IONIS-FXIrx administered to Patients with End-Stage Renal Disease on Hemodialysis in Fall 2016
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Nov 01, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 2 Study, End-stage Renal Disease, Hemodialysis, Ionis-fxi, Ionis-fxirx